Reportedly, Dishman Pharmaceuticals has started construction at its proposed SEZ site, near Ahmedabad, Gujrat, India, in the last week of March, after receiving funds from IDBI and Bank of Maharashtra, which is being executed by the company’s infrastructure arm Dishman Infrastructure.
JR Vyas, managing director, said that the company has received expression of interest from 15 Indian pharma companies and around 10 foreign companies, mostly from Europe and the US. The company also expects some Japanese companies to come to the SEZ due to its proximity to Dholera-SIR project and the Freight Corridor.
Dishman Pharmaceuticals said that it gave up its engineering SEZ because of the global recession, and also made changes to its SEZ project plans by consolidating the engineering SEZ land with pharma SEZ. The SEZ is said to be the second active SEZ in the state, after Zydus Cadila promoted SEZ-Pharmaez. Other major projects like PHASEZ (promoted by Cadila Pharma), Jubilant SEZ (promoted by Jubilant Organosys) and JB SEZ (promoted by JB Chemicals and IL&FS) are yet to gather momentum.
Mr Vyas added: “We have raised INR120-crore fund for the project. We are looking forward to raise another Rs 100 crore from leasing out plots in the SEZ to companies in next few months. We will raise additional funds once we are done with Phase-I,” reported the newspaper.